MK 0752

Drug Profile

MK 0752

Alternative Names: MK-0752

Latest Information Update: 15 Mar 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Cancer Research UK; Merck & Co
  • Class Antidementias; Antineoplastics; Propionates; Small molecules; Sulfones
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; CNS cancer; Pancreatic cancer; Solid tumours
  • Discontinued Alzheimer's disease; Haematological malignancies

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Mar 2016 MK 0752 is still in phase I development for Cancer
  • 01 Oct 2014 Cancer Research UK completes a phase I trial in Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease) in United Kingdom (NCT01098344)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top